Tumor-associated macrophages mediate gastrointestinal stromal tumor cell metastasis through CXCL2/CXCR2

Hongke Cai1, Yi Chen1, Xi Chen2

  • 1Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.

Cellular Immunology
|December 28, 2022
PubMed
Abstract

Insights

Tumor-associated macrophages (TAMs) secrete CXCL2, a chemokine that promotes gastrointestinal stromal tumor (GIST) metastasis. Targeting this CXCL2-TAM interaction may offer new immunotherapy strategies for GIST.

Area of Science:

  • Oncology
  • Immunology
  • Gastroenterology

Background:

  • Tumor-associated macrophages (TAMs) are implicated in solid tumor progression, but their role in gastrointestinal stromal tumors (GIST) is not fully understood.
  • The specific mechanisms by which TAMs influence GIST metastasis require further elucidation.

Purpose of the Study:

  • To investigate the role of TAM-derived chemokines in promoting metastasis within the GIST microenvironment.
  • To explore the potential of targeting TAMs and their secreted factors for GIST immunotherapy.

Main Methods:

  • Bioinformatic analysis of M2-TAM markers and CXCL2 expression in GIST tissues.
  • Immunofluorescence, ELISA, and flow cytometry to assess protein and cell marker expression.
  • In vitro cell function assays (viability, invasion, migration) and Western blot for EMT markers.
  • Establishment of a mouse liver metastasis model to confirm in vivo effects.

Main Results:

  • High expression of M2-TAM markers and CXCL2 was observed in metastatic GIST tissues, with co-localization of CXCL2 and TAM.
  • CXCL2 secreted by M2-TAMs promoted GIST cell invasion, migration, and epithelial-mesenchymal transition (EMT).
  • Blocking CXCL2 or silencing its receptor CXCR2 inhibited GIST metastasis in vitro and in vivo.

Conclusions:

  • This study reveals that M2-TAMs promote GIST metastasis by secreting CXCL2, highlighting a novel mechanism in the tumor microenvironment.
  • The findings provide a theoretical basis for developing targeted immunotherapies against M2-TAMs in GIST treatment.